{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:01:17Z","timestamp":1787022077984,"version":"build-2736575974"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grupo de Investigaci\u00f3n en Servicios Sanitarios de Arag\u00f3n","award":["B09-17R"],"award-info":[{"award-number":["B09-17R"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To analyze patterns of antihypertensive drug use among new users in a Southern European population, and identify patient- and treatment-related factors that influence persistence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective observational study of new antihypertensive drug users aged \u226540 years in Arag\u00f3n, Spain. Information on antihypertensive drugs (2014\u20132016) prescribed and dispensed at pharmacies via the public health system were collected from a regional electronic population-based pharmacy database. Persistence was assessed using the gap method. Kaplan-Meier and Cox regression analyses were conducted to analyze patterns of use and factors that influence persistence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 25,582 new antihypertensive drug users in Arag\u00f3n during the study period were prescribed antihypertensive drugs in monotherapy (73.3%), fixed combination (13.9%), free combination (9.1%), or other (3.7%). One in five received antihypertensive drugs within 15 days of the prescription date, but not after. During the first year of follow-up, 38.6% of the study population remained persistent. The likelihood of treatment discontinuation was higher for participants who were male, aged \u226580 years, and received an antihypertensive drug in monotherapy compared with fixed combination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Overall persistence with antihypertensive therapy was poor, and was influenced by the sex, age and type of therapy. Fixed combinations appear to be a good choice for initial therapy, especially in patients with a higher risk of discontinuation. Nonetheless, adverse drug effects and the patient\u2019s preferences and clinical profile should be taken into account.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0245610","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T18:03:46Z","timestamp":1610733826000},"page":"e0245610","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of patient and treatment factors on persistence with antihypertensive treatment: A population-based study"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7194-8275","authenticated-orcid":true,"given":"Sara","family":"Malo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7293-701X","authenticated-orcid":true,"given":"Isabel","family":"Aguilar-Palacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Feja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Lallana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Armesto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Rabanaque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"pone.0245610.ref001","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"D Ettehad","year":"2016","journal-title":"Lancet"},{"key":"pone.0245610.ref002","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.112.193078","article-title":"Achievement of cardiometabolic goals in aware hypertensive patients in Spain: a nationwide population-based study","volume":"60","author":"JR Banegas","year":"2012","journal-title":"Hypertension"},{"key":"pone.0245610.ref003","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"B Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0245610.ref004","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ahj.2013.09.014","article-title":"Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes","volume":"167","author":"NK Choudhry","year":"2014","journal-title":"Am Heart J"},{"key":"pone.0245610.ref005","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/jhh.2017.1","article-title":"Risk of acute myocardial infarction after discontinuation of antihypertensive agents: a case-control study","volume":"31","author":"FF Alharbi","year":"2017","journal-title":"J Hum Hypertens"},{"key":"pone.0245610.ref006","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40292-017-0221-4","article-title":"Improving Adherence to Treatment and Reducing Economic Costs of Hypertension: The Role of Olmesartan-Based Treatment","volume":"24","author":"FV Costa","year":"2017","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"pone.0245610.ref007","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1742-1241.2007.01630.x","article-title":"The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review","volume":"62","author":"JA Cramer","year":"2008","journal-title":"Int J Clin Pract"},{"key":"pone.0245610.ref008","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jdiacomp.2013.07.007","article-title":"Observational research\u2014opportunities and limitations","volume":"27","author":"EJ Boyko","year":"2013","journal-title":"J Diabetes Complications"},{"key":"pone.0245610.ref009","doi-asserted-by":"crossref","first-page":"e4908","DOI":"10.1097\/MD.0000000000004908","article-title":"Persistence to antihypertensive drug classes: A cohort study using the Swedish Primary Care Cardiovascular Database (SPCCD)","volume":"95","author":"M Qvarnstrom","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"pone.0245610.ref010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/jch.13240","article-title":"Fixed-dose vs free-dose combinations for the management of hypertension-An analysis of 81 958 patients","volume":"20","author":"P Bramlage","year":"2018","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"pone.0245610.ref011","doi-asserted-by":"crossref","first-page":"e011650","DOI":"10.1136\/bmjopen-2016-011650","article-title":"Comparison of therapy persistence for fixed versus free combination antihypertensives: a retrospective cohort study","volume":"6","author":"T Grimmsmann","year":"2016","journal-title":"BMJ Open"},{"key":"pone.0245610.ref012","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00228-007-0340-2","article-title":"Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study","volume":"63","author":"J Hasford","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"pone.0245610.ref013","first-page":"1","article-title":"Prescribing pattern of antihypertensive drugs in two European cohorts: a population-based database study","author":"S Malo","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"pone.0245610.ref014","volume-title":"ATC\/DDD Index","year":"2018"},{"key":"pone.0245610.ref015","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/03007995.2017.1321534","article-title":"Different approaches to the assessment of adherence and persistence with cardiovascular-disease preventive medications","volume":"33","author":"S Malo","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"pone.0245610.ref016","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2147\/PPA.S164819","article-title":"Adherence to chronic medication in older populations: application of a common protocol among three European cohorts","volume":"12","author":"E Menditto","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"pone.0245610.ref017","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/sj.jhh.1002223","article-title":"Persistence and adherence with antihypertensive drug therapy in a German sickness fund population","volume":"21","author":"A Hoer","year":"2007","journal-title":"J Hum Hypertens"},{"key":"pone.0245610.ref018","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cjca.2014.03.017","article-title":"Antihypertensive drug prescribing and persistence among new elderly users: implications for persistence improvement interventions","volume":"30","author":"K Tu","year":"2014","journal-title":"Can J Cardiol"},{"key":"pone.0245610.ref019","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/qshc.2003.005926","article-title":"Patients' problems with new medication for chronic conditions","volume":"13","author":"N Barber","year":"2004","journal-title":"Qual Saf Health Care"},{"key":"pone.0245610.ref020","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"36","author":"B Williams","year":"2018","journal-title":"J Hypertens"},{"issue":"12","key":"pone.0245610.ref021","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/pds.4884","article-title":"Effectiveness of two\u2010drug therapy versus monotherapy as initial regimen in hypertension: A propensity score\u2010matched cohort study in the UK Clinical Practice Research Datalink","volume":"28","author":"K Marinier","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"pone.0245610.ref022","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/HYPERTENSIONAHA.118.11308","article-title":"Initial Antihypertensive Treatment Strategies and Therapeutic Inertia","volume":"72","author":"F Rea","year":"2018","journal-title":"Hypertension"},{"key":"pone.0245610.ref023","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12872-017-0665-4","article-title":"Persistence with antihypertensives in uncomplicated treatment-naive very elderly patients: a nationwide population-based study","volume":"17","author":"KH Choi","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"pone.0245610.ref024","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/bcp.13692","article-title":"Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: A UK population-based study","volume":"84","author":"SH Mahmoudpour","year":"2018","journal-title":"Br J Clin Pharmacol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T18:03:56Z","timestamp":1610733836000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245610"}},"subtitle":[],"editor":[{"given":"Hans-Peter","family":"Brunner-La Rocca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0245610","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]}}}